Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction results of the I-PRESERVE collagen substudy

Circulation: Heart Failure

Volumn 4, Issue 5, 2011, Pages 561-568

  Krum, Henry ^a   Elsik, Maros ^a   Schneider, Hans G ^b   Ptaszynska, Agata ^c   Black, Marion ^b   Carson, Peter E ^d   Komajda, Michel ^e   Massie, Barry M ^f   McKelvie, Robert S ^g   McMurray, John J ^h   Zile, Michael R ⁱ   Anand, Inder S ^j  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BRISTOL MYERS SQUIBB   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Collagen; Diastolic pressure; Fibrosis; Heart failure; Osteopontin; Ventricular ejection fraction

Indexed keywords

COLLAGEN TYPE 1; IRBESARTAN; OSTEOPONTIN; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BIPHENYL DERIVATIVE; COLLAGEN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; DEATH; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VASCULARIZATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBROSIS; HEART MUSCLE; HEART STROKE VOLUME; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; COLLAGEN; DOUBLE-BLIND METHOD; FEMALE; FIBROSIS; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MYOCARDIUM; OSTEOPONTIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; STROKE VOLUME; SURVIVAL RATE; TETRAZOLES;

EID: 81855171057     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.960716     Document Type: Article

References (19)

1. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the National Heart, Lung and Blood Institute. Circulation. 2009;119:3070-3077.
2. Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277-1282. (Pubitemid 33032998)
3. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-895. (Pubitemid 46294729)
4. Borbély A, Papp Z, Edes I, Paulus WJ. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep. 2009;61:139-145.
5. Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56:89-97.
6. Querejeta R, Varo N, López B, Larman M, Artiano E, Etayo JC, Martínez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindán JP, Díez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735. (Pubitemid 30196635)
7. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001;38:1222-1226. (Pubitemid 34252835)
8. Zannad F, Alla F, Dousset B, Perez A, Pitt B; RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation. 2000;102:2700-2706.
9. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263-1268. (Pubitemid 39202343)
10. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; I-PRESERVE Investigators. The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005;11:576-585. (Pubitemid 41463727)
11. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004;64:24-31. (Pubitemid 39208920)
12. Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A, Borro M, Simmaco M, Salvati A, De Biase L, Volpe M. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol. In press.
13. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
14. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820. (Pubitemid 24223231)
15. Mak GJ, Ledwidge MT, Watson Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54:1674-1682.
16. Krum H, Zhang M, Connelly K, Gilbert RE, Kelly DJ. Abstract 315: Directly targeting myocardial fibrosis with FT-011 improves cardiac remodeling in experimental diabetic cardiomyopathy. Circulation. 2008;118:S-283.
17. Rossi A, Cicoira M, Golia G, Zanolla L, Franceschini L, Marino P, Graziani M, Zardini P. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart. 2004;90:650-654. (Pubitemid 38668539)
18. Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest. 2005;28(10 suppl):8-13.
19. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep. 2001;3:12-18.